Member Info for BuenaVista

Don't you mean a way out of your gamble? Admit it, you bought here hoping to get a quick profit and now you find your stake trapped, all £574 of it.

Yes. As I put in my last post.

D-G, so I suggested you put it to Chris.Coughlin that she contact the guy about his interests, thus the "the guy's name, email address, and his rôle within the charity."

I don't know what Avacta's strict definition of SGC is but ACC patients have been included in the trial, for example:

https://www.investormeetcompany.com/meeting/phase-1b-faridoxorubicin-ava6000-salivary-gland-cancer-data-release/presentation.pdf of 17 December 2025, including histology (slides 15 & 16)

D-G, maybe drop Chris a line with the guy's name, email address, and his rôle within the charity. Chris had previously said that patient advocacy groups were important input contacts for Avacta and I think an approach from her would impress him.

The ASCO data was very largely about the lifting of the lifetime limit. Now that that has been done, Bio Intl will hopefully now concentrate on PFS and targetting as they will have an extra few weeks of data/scans/histology.

Yeah I saw that this morning. Second item on the BBC News website, extolling the virtues of an ADC complete with illustrative diagrams. The warhead is DM4 and the company is AbbVie, which used to be the biopharma part of Abbott Laboratories. So not really the wondrous tech breakthrough that AbbVie's well funded PR department are making it out to be. Just another ADC with the usual ADC issues.

Well I'm taking a lot of that technical talk in the video on trust!

Also here: https://www.investormeetcompany.com/updates/faridoxorubicin-program/show

AKA The S-Curve. Slow at first then fast then slow again at the top.

These are the two indications that were talked about being added — colorectal cancer and HR+ breast cancer — are they not.

Estimated enrolment increased from 144 to 174, which will allow for the additional indications. However it also shows confidence that there will be the funding available for his enlargement of the trial.

ASCO 2026 is full of 'successful' treatments. That's kind of the point of the conference. If anyone is concerned about a seemingly successful cancer treatment being reported, look at the efficacy and the side effects and consider whether they could be improved by making the active agent into a targetted pre|CISION prodrug. To do this, to make the judgement, compare with the cancer indication's current treatment success rate and the side-effects associated with drugs in the same class as the active agent's mechanism of action.

Yeah, clinical stuff chugging along nicely but only financing will shift the share price.

Other than that there's not much to say except that the 3 amigos are twats.

@teabag66 tripe not completely gone yet.

Totally agree VR. All those scroungers at Avacta should not only not be paid a penny; they should pay their way and I think £10,000 a year is a fair, perhaps overly generous amount, that should be levied on them for the honour of working at Avacta, the £200, 000 thus collected to be distributed to share holders as a special dividend you absolute moron with knob for a brain.

I've also reported the remaining eggy posts which are just packs of lies. Repeated postings of fabrications should not be allowed. That goes from false/misleading information to disruptive behaviour. I suggest all genuine investors report these eggy posts. It doesn't take long and is the only way to remove the lies.

You need to include the molecular weight ratio of doxorubicin to faridox, which is 54:80, on order to convert the faridox dose into the amount of bound doxorubicin it contains.

310 x (54/80) = 209.25 which is 2.79 times the standard (highest) 75 dox dose.

@JRDC, they could split the oncology market up using exclusive licence agreements for particular indications. That would allow them to license out faridox for SGC with first dibs on any other Avacta candidate.

^selling

Thanks eggy, TW's thoughts are always good for a laugh.

Just traders along their golden eggs. Their choice, their loss.